These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 15681532)

  • 21. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
    Fattoruso SI; Visca P; Lopez M
    Clin Ter; 2008; 159(5):361-7. PubMed ID: 18998038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
    Labropoulos SV; Fletcher JA; Oliveira AM; Papadopoulos S; Razis ED
    Anticancer Drugs; 2005 Apr; 16(4):461-6. PubMed ID: 15746584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dermatofibrosarcoma protuberans: report of a case with a variant ring chromosome and metastases following pregnancy.
    Bigby SM; Oei P; Lambie NK; Symmans PJ
    J Cutan Pathol; 2006 May; 33(5):383-8. PubMed ID: 16640548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermatofibrosarcoma protuberans is CD117 negative even after extreme antigen retrieval conditions.
    Fernandez-Flores A
    Rom J Morphol Embryol; 2007; 48(4):419-21. PubMed ID: 18060194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
    Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
    Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays.
    Patel KU; Szabo SS; Hernandez VS; Prieto VG; Abruzzo LV; Lazar AJ; López-Terrada D
    Hum Pathol; 2008 Feb; 39(2):184-93. PubMed ID: 17950782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors].
    Bianchini L; Maire G; Pedeutour F;
    Bull Cancer; 2007 Feb; 94(2):179-89. PubMed ID: 17337387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
    McArthur G
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
    Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
    J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
    Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
    J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
    Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
    Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
    Baars A; Pinedo HM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2072-6. PubMed ID: 14606355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
    Rubin BP; Schuetze SM; Eary JF; Norwood TH; Mirza S; Conrad EU; Bruckner JD
    J Clin Oncol; 2002 Sep; 20(17):3586-91. PubMed ID: 12202658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
    Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
    Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
    Shimizu A; O'Brien KP; Sjöblom T; Pietras K; Buchdunger E; Collins VP; Heldin CH; Dumanski JP; Ostman A
    Cancer Res; 1999 Aug; 59(15):3719-23. PubMed ID: 10446987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.
    Price VE; Fletcher JA; Zielenska M; Cole W; Viero S; Manson DE; Stuart M; Pappo AS
    Pediatr Blood Cancer; 2005 May; 44(5):511-5. PubMed ID: 15503291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
    Koseła-Paterczyk H; Rutkowski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
    Johnson-Jahangir H; Sherman W; Ratner D
    J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.